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Abstract
In response to DNA damage, signaling pathways are triggered
that either block the cell division cycle at defined transitions
(G1-S and G2-M) or slow down progression through the
S phase. Nucleases play important roles in DNA synthesis,
recombination, repair, and apoptosis. In this study, we have
examined the regulation of human exonuclease 1 (hEXO1b).
The endogenous hEXO1b protein was only detected upon
enrichment by immunoprecipitation. We found that hEXO1b
was constantly expressed throughout the cell cycle. However,
treatment of cells with agents that cause arrest of DNA
replication led to rapid degradation of hEXO1b. This effect
was fully reversed upon removal of the block. Analysis of
synchronized cells showed that degradation of hEXO1b
during the S phase was strictly dependent on DNA synthesis
inhibition. DNA damage caused by UV-C radiation, ionizing
radiation, cisplatin, or the alkylating agent N-methyl-NV-
nitro-N-nitrosoguanidine did not affect hEXO1b stability. We
show that hEXO1b was phosphorylated in response to
inhibition of DNA synthesis and that phosphorylation
coincided with rapid protein degradation through ubiqui-
tin-proteasome pathways. Our data support the evidence that
control of exonuclease 1 activity may be critical for the
maintenance of stalled replication forks. (Cancer Res 2005;
65(9): 3604-9)
Introduction
Nucleases play important roles in DNA synthesis, recombination,
repair, and apoptosis. Exonuclease-1 (Exo1) was originally identified
in Schizosaccharomyces pombe (1) as a member of the Rad2 family
of structure-specific nucleases (2). Saccharomyces cerevisiae Exo1
was found to be highly transcribed in meiosis and the encoded
protein was shown to participate in processing double-strand break
ends as well as in meiotic crossover (3). The sequence of the human
homologue of S. cerevisiae Exo1 gene revealed only 27% identity at
the amino acid level (4). Nonetheless, human exonuclease 1
(hEXO1) was shown to be functionally similar to the yeast protein
by its ability to complement S. cerevisiae Exo1p (5). Two isoforms of
hEXO1 (hEXO1a and hEXO1b) were described to arise from
alternative splicing, although no functional differences between
the two products have yet been observed (6).
Exonuclease 1 catalyzes the removal of mononucleotides from
the 5V end of the DNA duplex, showing a strong preference for
blunt-ended, 5V-recessed termini and DNA nicks. It can also
exonucleolytically degrade ssDNA although less efficiently than
double-stranded DNA. Moreover, hEXO1b displays a 5V-ssDNA-flap-
specific endonuclease activity (2, 7).
Mismatch repair is a postreplication DNA repair mechanism that
is implicated in reducing the rate of somatic microsatellite
polymorphism and is disabled in a number of human tumors (8).
S. pombe Exo1p was shown to play a key role in mismatch
correction and mutation avoidance (9). Physical and genetic
interaction between yeast Exo1p and the proteins Msh2p (10)
and Mlh1p (11) provided direct evidence for the functional and a
structural role of Exo1p in mismatch repair (12). Interaction with
mismatch repair proteins was also observed in human cells where
hEXO1 formed a complex with hMLH1/hPMS2 (13). Studies
conducted with reconstituted systems pointed to hEXO1 as the
most likely candidate for the excision step during mismatch repair
in mammals (4, 14, 15). In addition to its role in the mismatch
repair system, S. cerevisiae Exo1p was shown to be involved in
mitotic recombination (16) and end resection at unprotected
telomeres (17). A role for hEXO1 in resolving DNA intermediates
formed during recombination was suggested by the finding that the
protein physically interacted with the Werner syndrome helicase
(18). Colocalization of ectopically expressed hEXO1 with prolifer-
ating cell nuclear antigen (PCNA) further pointed to a potential
role for hEXO1 in controlling events at sites of replication (19). The
involvement of hEXO1 in the control of key metabolic processes is
emphasized by the phenotype of Exo1/ mice that displayed
reduced survival, sterility, and increased susceptibility to the
development of lymphomas (20). Analysis of Exo1/ mouse cells
revealed specific defects in mismatch repair leading to elevated
microsatellite instability, increase in mutation rate at the Hprt
locus, abnormal spindle structures in metaphase cells (20), altered
somatic hypermutation, and reduced class switch recombination
(21). In this study, we provide evidence that hEXO1b is destabilized
in response to replication fork arrest by hydroxyurea and
aphidicolin but not upon generation of adducts in DNA or
double-strand breaks. We show that rapid hEXO1b protein
degradation occurs via an ubiquitin-mediated proteasome pathway
and is facilitated by phosphorylation.
Materials and Methods
Expression vectors, chemicals, and antibodies. The coding region
of hEXO1b (codons 1-846) was amplified by PCR using human EXO1b cDNA
as template and the primers 5V-GGGAATTCCATATGGGGATACAGG-
GATTGCTA-3V ( forward) and 5V-AAGGCCGCTCTTCCGCACATCTGGAA-
TATTGCTCTTTGAACACGG-3V (reverse). The PCR product was inserted
between the NdeI and SapI sites of the pTXB1 plasmid (NEB) to construct
a translational fusion between hEXO1b and a self-cleaving affinity tag that
is composed of an Mxe intein fragment and the chitin-binding domain.
A plasmid encoding a fusion between the NH2-terminal region of hEXO1b
(codons 1-391) and Mxe–chitin-binding domain was constructed in the
same way as indicated above using the primers 5V-GGGAATTCCATATGGG-
GATACAGGGATTGCTA-3V ( forward) and 5V-AAGGCCGCTCTTCCGCAC-
TTCAATTGTGGGGCATCTGA-3V(reverse). An additional methionine codon
Requests for reprints: Stefano Ferrari, Institute of Molecular Cancer Research,
University of Zurich, August Forel Street 7, CH-8008 Zurich, Switzerland. Phone: 41-1-
634-8943; Fax: 41-1-634-8904; E-mail: sferrari@imcr.unizh.ch.
I2005 American Association for Cancer Research.
Cancer Res 2005; 65: (9). May 1, 2005 3604 www.aacrjournals.org
Research Article
was placed between hEXO1b and the affinity tag according to the manu-
facturer’s instructions. Human EXO1a was generated as indicated above
using the primers 5V-GGGAATTCCATATGGGGATACAGGGATTGCTA-3V
( forward) and 5V-AAGGCCGCTCTTCCGCAGAATTTTTTAAATCCAAA-
GTTTTTC-3V (reverse). Constructs were verified by sequencing. Recombi-
nant hEXO1b, hEXO1b 1-391, and hEXO1a proteins were produced in the
Escherichia coli BL21-CodonPlus-(DE3)-RIL cells (Stratagene, La Jolla, CA)
harboring the plasmids described above and purified using chitin beads as
previously described (22). Expressed proteins were further purified on a 5 mL
HighTrap SP column (Amersham Pharmacia, Uppsala Sweden) equilibrated
with a buffer containing 50 mmol/LTris-HCl (pH 7.5), 150 mmol/L NaCl, 10%
(v/v) glycerol, 0.1 mmol/L EDTA, and 1 mmol/L DTT. Proteins were eluted
with a linear concentration gradient of NaCl (0.2-0.45 mol/L; 50 mL) and
stored at 80jC.
Full-length human EXO1b cDNA was subcloned in the mammalian
expression vector pcDNA3.1/His (Invitrogen, Carlsbad, CA) between the
BamHI and EcoRV sites. A polyclonal antibody to hEXO1b 1-391 (F-15) was
generated in rabbit (Clonestar, Brno, Czech Republic) and purified using a
protein A-Sepharose column (Amersham Pharmacia) according to the
manufacturer’s instructions. A monoclonal antibody to full-length Exo1b
(Ab-4, clone 266) was purchased from NeoMarkers (Fremont, CA).
Antibodies to hChk1-pSer345 and hChk2-pThr68 were from Cell Signaling
Technology (Beverly, MA). Antibodies to TFIIH (sc-293) and hChk2 were
from Santa Cruz Biotechnology (Santa Cruz, CA) and Upstate Biotechnology
(Charlottesville, VA), respectively. Monoclonal antibodies to immunoprecip-
itate and detect hMSH6 by Western blot were clone 66H6 and clone
44 (Transduction Laboratories, Newington, NH), respectively. Hydroxyurea,
cisplatin, aphidicolin, and nocodazole were obtained from Sigma (St. Louis,
MO) and dissolved in water or DMSO as specified by the manufacturer.
MG132 and okadaic acid were purchased from Calbiochem (San Diego, CA)
and dissolved in DMSO. Ubiquitin was detected with monoclonal antibody
12CA5 to the HA tag.
Cell culture. HEK 293T and HeLa cells were maintained in DMEM
(OmniLab, Mettmenstetten, Switzerland) supplemented with 10% FCS (Life
Technologies, Rockville, MD), penicillin (100 units/mL), and streptomycin
(100 Ag/mL; complete medium). For synchronization experiments, cells
were seeded at 2  106 in 10 cm plates and treated after 24 hours with 300
ng/mL nocodazole for 16 hours. Cells were washed thrice with PBS,
released in complete medium, and harvested at the time points indicated in
figure legends. DNA content was analyzed by flow cytometric analysis
(Cytomics FC 500, Beckman Coulter, Fullerton, CA).
Western blotting and immunoprecipitation. Cellular proteins were
extracted using ice-cold buffer A [50 mmol/L Tris-HCl (pH 7.5), 120 mmol/L
NaCl, 20 mmol/L NaF, 1 mmol/L EDTA, 6 mmol/L EGTA, 15 mmol/L Na-PPi,
0.5 mmol/L Na-orthovanadate, 1 mmol/L benzamidine, 0.1 mmol/L phenyl-
methylsulfonyl fluoride, 1% Nonidet P-40]. Protein concentration was
determined using the Bio-Rad Protein Assay Reagent (Bio-Rad, Hercules,
CA). Detection of proteins by Western blot analysis was done following
separation of whole cell extracts (50 Ag) on 8% SDS-polyacrylamide gels.
Proteins were transferred to polyvinylidene difluoride (PVDF, Amersham-
Pharmacia), probed with appropriate antibodies and immune complexes
revealed using the enhanced chemiluminescence system (Amersham Phar-
macia). EXO1b was immunoprecipitated from 2 mg total cell extracts for
3 hours at 4jC using the polyclonal antibody F-15. The antibody was captured
using protein A agarose beads (AmershamPharmacia) for 1 hour at 4jC. Beads
were washed in 2  1 mL TNET ice-cold buffer [50 mmol/L Tris-HCl (pH 7.5),
140 mmol/L NaCl, 1% Triton X-100] followed by 2  1 mL ice-cold TNE buffer
[50 mmol/LTris-HCl (pH 7.5), 140 mmol/L NaCl] and heated for 10 minutes at
95jC in 2  Laemmli sample buffer. Immunoprecipitated proteins were
analyzed by Western blotting using the monoclonal Ab-4 antibody.
Detection of protein ubiquitinylation. The protocol used to examine
hEXO1b ubiquitinylation was designed to eliminate all noncovalent protein
interactions. Cells transfected with pcDNA3-HA-ubiquitin plasmid were
lysed in buffer B [50 mmol/L Tris-HCl (pH 7.5), 5 mmol/L DTT, 1% SDS]
and immediately boiled for 10 minutes. Samples were clarified by
centrifugation for 10 minutes at 14,000 rpm and diluted with 4 volumes
of buffer A before immunoprecipitation.
Phosphatase treatment. Protein A agarose–bound immunocomplexes,
obtained as indicated above, were subjected to dephosphorylation for
15 minutes at 37jC using 2 to 5 units of calf intestinal phosphatase (NEB) in
1  NEB buffer 3. Control reactions were done by inclusion of phosphatase
inhibitors (0.5 mmol/L sodium orthovanadate; 5 mmol/L p-nitrophenyl-
phosphate).
In vivo labeling of cells. HEK 293T cells were grown in DMEM
containing 10% FCS to 80% confluence and either left untreated or treated
with hydroxyurea for 18 hours. MG132 was present during the last 15 hours
of incubation. Cells were starved for 1 hour in phosphate-free DMEM
containing 1% dialyzed FCS followed by incubation for the last 4 hours in
the same medium with the addition of 1 mCi [32P]Pi. Cell extracts were
immunoprecipitated using polyclonal antibody F-15; proteins were resolved
by SDS-PAGE and transferred to PVDF. Radioactive proteins were
visualized using a PhosphorImager (Amersham Pharmacia) and hEXO1b
was detected by Western blotting with monoclonal antibody Ab-4.
Results
Characterization of antibodies to hEXO1b. As prerequisite to
exploring the effect of DNA damage on hEXO1, we set out to
characterize the expression of endogenous hEXO1 protein. The
polyclonal antibody F-15 could detect recombinant hEXO1b protein
expressed in E. coli (Fig. 1A , lanes 1 and 2) and hEXO1b ectopically
expressed in 293T cells (Fig. 1A , lane 7) that were used as positive
controls. However, neither monoclonal antibody Ab-4 (data not
shown) nor our F-15 polyclonal antibody was able to detect
endogenous hEXO1 in HEK 293T (Fig. 1A , lanes 4 and 5), HeLa,
U2-OS cells, or human fibroblasts (data not shown). Endogenous
Figure 1. Inhibitors of DNA replication induce hEXO1b destabilization.
A, Western blot analysis of hEXO1b was done using antibody F-15. Lanes 1 to 3,
recombinant hEXO1b purified from E. coli (100, 25, and 10 ng, respectively);
lanes 4 and 5, total cell lysate (50 Ag) from HEK 293T cells that were left
untreated or treated with hydroxyurea; lanes 6 and 7, total cell lysate (50 Ag)
from HEK 293T cells that were mock transfected or transfected with an
expression vector encoding hEXO1b. B, HEK 293T cells were treated in the
absence (lane 1 ) or the presence (lane 2) of hydroxyurea (2 mmol/L) for
24 hours. Endogenous hEXO1b was immunoprecipitated using polyclonal antibody
F-15 and probed with monoclonal antibody Ab-4 (top). Immunoprecipitation of
MSH6 from the same extracts was used as control (middle). Detection of TFIIH
in the whole cell extract served to ensure that equal amount of protein was
used for immunoprecipitation (bottom). C, the electrophoretic migration of
recombinant hEXO1b (100 ng, lane 1) or hEXO1a (125 ng, lane 2) purified from
E. coli was compared with the migration of the protein immunoprecipitated
from 293T cells with antibody F-15, lane 3 . Detection was done with monoclonal
antibody Ab-4. D, HEK 293T cells were either left untreated (lane 1) or treated
with 2 mmol/L hydroxyurea for 16 hours (lanes 2-8). Upon release from the
hydroxyurea block (lanes 3-8), hEXO1b protein level was monitored by
immunoprecipitation at the indicated time points.
hEXO1b Stability and Replication Fork Arrest
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hEXO1 could only be detected through combined immunoprecip-
itation with rabbit polyclonal serum F-15 followed by Western
blotting using monoclonal antibody Ab-4 (Fig. 1B , top). Although
monoclonal antibody Ab-4 could detect both splice variants hEXO1a
and hEXO1b, expressed and purified from E. coli , the endogenous 1a
isoform was undetectable upon immunoprecipitation from 293T
cells (Fig. 1C , lane 3). The apparent difficulty of detecting hEXO1b in
cell extracts using Western blotting was the result of low abundance
of the protein in the cell (f100 ng in 3mg cell extract; Fig. 1C , lane 3)
and low affinity of available antibodies (Fig. 1A , lanes 1-3).
hEXO1b is degraded in response to hydroxyurea. Treatment
of cells with hydroxyurea, which causes replication fork arrest due to
depletion of the pool of deoxynucleotides, led to clear decrease in the
amount of immunoprecipitated hEXO1b protein (Fig. 1B , lane 2
versus1). ImmunoprecipitationofhMSH6 fromthesamecell extracts
was used as internal control to ensure reliability and accuracy of the
procedure (Fig. 1B , middle). The correlation between hEXO1b
degradation and replication fork arrest was further confirmed by
time course recovery experiments where hEXO1b protein level was
examined upon removal of hydroxyurea. The data showed that
hEXO1b returned to regular levels within 8 hours of hydroxyurea
removal (Fig. 1D), thus indicating the reversibility of the effect.
DNA damage does not affect hEXO1b protein stability. To
distinguish whether destabilization of hEXO1b was the result of
hydroxyurea-dependent fork arrest, or rather the consequence of
secondary lesions occurring at stalled forks, we examined the
effect of different genotoxic agents. Treatment of HEK 293T cells
with UV-C (20 J/m2), ionizing radiation (10 Gy), or cisplatin
(7 Amol/L; Fig. 2A) did not reduce hEXO1b protein level, thus
indicating that destabilization of hEXO1b was a specific response
to replication stress. Western blot analysis of proteins involved in
the DNA damage response confirmed that damage generated by
genotoxic agents, such as ionizing radiation, UV-C, and cisplatin,
was properly signaled (Fig. 2B). Furthermore, damage generated
with the alkylating agent N-methyl-NV-nitro-N-nitrosoguanidine
(MNNG) at doses that cause cell cycle arrest at G2 in a mismatch
repair–dependent manner (23) did not affect hEXO1b protein
level (Fig. 2C , lane 4). To further substantiate these findings, we
treated cells with aphidicolin, a drug that causes stalling of the
replication fork through inhibition of Pol-a and Pol-y. As
observed with hydroxyurea (Figs. 1B and 2C , lane 2), aphidicolin
treatment also resulted in hEXO1b protein degradation (Fig. 2C ,
lane 3).
hEXO1b degradation is S phase specific and depends on
inhibition of DNA replication. To rule out the possibility that the
effects of hydroxyurea or aphidicolin on hEXO1b protein level would
merely result from synchronization of the cells in early S phase, we
examined the pattern of hEXO1b expression during transition
through the cell division cycle. Analysis of hEXO1b during
progression through the cell cycle, which was monitored by f low
cytometric analysis (Fig. 3A), showed that hEXO1b protein was
Figure 2. DNA damage does not affect hEXO1b protein stability.
A, immunoprecipitation of hEXO1b from untreated cells (lane 1) or cells
treated with 10 Gy ionizing radiation (IR , top ), 20 J/m2 UV-C (UV , middle ), or
7 Amol/L cisplatin (CDDP , bottom ). B, phosphorylation of CHK1 and CHK2
in response to ionizing radiation, UV-C, cisplatin, or hydroxyurea was confirmed
by Western blot analysis of total cell extract using CHK1-pS345 and CHK2-pT68
antibodies. C, immunoprecipitation of hEXO1b from untreated cells (lane 1 )
or cells treated with 2 mmol/L hydroxyurea (24 hours, lane 2), 5 Ag/mL
aphidicolin (20 hours, lane 3 ), or 0.5 Amol/L MNNG (32 hours, lane 4).
Phosphorylation of CHK1 and CHK2 was taken as indication of the DNA
damage response.
Figure 3. hEXO1b protein is constantly expressed during the cell cycle and its
destabilization by DNA replication inhibitors is S phase specific. Exponentially
growing (Exp. ) HEK 293T cells were synchronized by treatment with nocodazole
(300 ng/mL) for 16 hours and released into the cell cycle. A, flow cytometric
analysis of DNA was done at the time points indicated. B, extracts from the cells
shown in (A ) were immunoprecipitated using polyclonal antibody F-15 and
analyzed by Western blotting using monoclonal antibody Ab-4. C, HEK 293T
cells were synchronized by treatment with nocodazole (300 ng/mL) for 16 hours.
Cells were released for 5 hours (M-G1 cells, lanes 1 -4) or 14 hours (S-phase
cells, lanes 5-8 ); at these time points, cells were left untreated (lanes 1 and 5 ) or
treated in the presence of 5 Ag/mL aphidicolin as indicated. Cell extracts were
immunoprecipitated and analyzed by Western blotting as in (B ).
Cancer Research
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invariantly present at all time points examined (Fig. 3B). We next
assessed whether the destabilization of hEXO1b following hydroxy-
urea or aphidicolin treatment was a specific response to the
inhibition of DNA synthesis or the result of other types of stress. To
this end, we treated cells proceeding fromM to G1 or cells in S phase
with aphidicolin. The data showed that the drug caused rapid
degradation of hEXO1b only if administered to S-phase cells,
whereas hEXO1b protein level remained substantially constant if the
treatment was done in cells progressing fromM to G1 when no DNA
synthesis occurs (Fig. 3C).
hEXO1b is polyubiquitinylated in response to hydroxyurea.
Rapid changes in cellular protein level might be the result of
transcriptional, translational, or posttranslational mechanisms. To
distinguish among these possibilities, we began by analyzing
hEXO1b protein stability. Addition of the selective proteasome
inhibitor MG132 showed an evident stabilization of hEXO1b
protein in hydroxyurea-treated cells (Fig. 4A , lanes 5-8 versus
lanes 1-4). These results confirmed our observation that hEXO1b
was particularly unstable under conditions of stalled replication
forks. To assess the involvement of ubiquitinylation in the control
of hEXO1b level, we transfected HEK 293T cells with a plasmid
encoding HA-tagged ubiquitin and examined hEXO1b protein upon
hydroxyurea treatment. Immunoprecipitation of hEXO1b under
conditions that eliminate all possible protein-protein interactions
(see Materials and Methods), and therefore rule out the presence of
contaminating proteins, showed that upon hydroxyurea treatment
endogenous hEXO1b was polyubiquitinylated (Fig. 4B , top). This
result suggested that hEXO1b degradation was mediated by
ubiquitin-proteasome pathways.
Phosphorylation of hEXO1b in response to hydroxyurea
coincides with protein degradation. Upon close examination, we
noticed that hEXO1b electrophoretic mobility was altered
in hydroxyurea-treated cells compared with untreated cells
(Fig. 5A , bottom , lanes 1 and 2). The retarded migration of hEXO1b
was abolished upon dephosphorylation of immunoprecipitated
hEXO1b with alkaline phosphatase (Fig. 5A , top and bottom , lane 3)
and was left unchanged upon inclusion of phosphatase inhibitors
Figure 4. Inhibition of DNA replication triggers polyubiquitinylation of hEXO1b.
A, exponential HEK 293T cells were either left untreated (time 0) or treated
with 2 mmol/L hydroxyurea. The proteasome inhibitor MG132 (10 Amol/L) was
added during the last 15 hours of incubation (6 hours in lanes 5 and 6).
B, HEK 293T cells were either mock transfected or transfected with a plasmid
encoding HA-tagged ubiquitin and treated in the presence or the absence of
hydroxyurea. MG132 was added as indicated above to block hEXO1b
degradation and allow detection of the protein. Cells were examined at the
time points indicated. Immunoprecipitated hEXO1b was analyzed by Western
blotting using an antibody to the HA-tag (top ) and the membrane was reprobed
with monoclonal antibody Ab-4 after stripping (bottom ). The smear >100 kDa
indicated the presence of polyubiquitinylated hEXO1b.
Figure 5. hEXO1b destabilization is phosphorylation-dependent and is
rescued by caffeine. A, top, immunoprecipitation of hEXO1b from untreated cells
(lanes 1 and 5 ) or cells treated for 24 hours with 2 mmol/L hydroxyurea (lanes
2 -4). In all cases, cells were treated for the last 15 hours of incubation with
10 Amol/L MG132 to rescue hEXO1b degradation. Dephosphorylation with calf
intestinal phosphatase (CIP ) in the presence or the absence of phosphatase
inhibitors (CIP-inh ) is indicated. Bottom, as in the top panel, with the exception
that cells were treated for 8 hours with hydroxyurea in the absence of
MG132. Proteins were resolved on 6% SDS-PAGE. B, HEK 293T cells were
treated with 10 Amol/L MG132 in the presence or the absence of 2 mmol/L
hydroxyurea for 15 hours. Metabolic labeling with 32Pi was done during the last
4 hours of incubation. Endogenous hEXO1b was immunoprecipitated and
detected by Western blot analysis (left ). Radioactive proteins were visualized
with a Phosphor Imager (right ). C, immunoprecipitation of hEXO1b from
untreated cells (lane 1) or cells treated for 6 hours with 2 mmol/L caffeine
(lane 2 ), 2 mmol/L hydroxyurea (lane 3 ), or 2 mmol/L caffeine followed by
2 mmol/L hydroxyurea (lane 4 ). Phosphorylation of CHK1 and CHK2 was
monitored to control the cellular response to hydroxyurea. D, immunoprecipitation
of hEXO1b from untreated cells (lane 1 ) or cells treated for 6 hours with
50 nmol/L okadaic acid (lane 2 ), 10 Amol/L MG132 (lane 3 ), 2 mmol/L
hydroxyurea (lane 4), 50 nmol/L okadaic acid followed by 2 mmol/L hydroxyurea
(lane 5 ), or 10 Amol/L MG132 followed by 2 mmol/L hydroxyurea (lane 6).
The immunoprecipitates were analyzed by Western blotting using monoclonal
antibody Ab-4.
hEXO1b Stability and Replication Fork Arrest
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(Fig. 5A , top and bottom , lane 4). To further substantiate this finding,
we labeled cells with 32Pi. The radiolabeled isotope was added to
untreated or hydroxyurea-treated cells during the last 4 hours of
incubation. Immunoprecipitation experiments showed that endog-
enous hEXO1b was a phosphoprotein and that phosphorylation was
moderately increased upon treatment with hydroxyurea (Fig. 5B ,
right). To address the possible link between hydroxyurea-induced
hEXO1b phosphorylation and protein stability, we examined the
effect of the ATM/ATR inhibitor caffeine on hEXO1b level. We
observed that treatment of cells with caffeine before the addition of
hydroxyurea rescued the hEXO1b protein from degradation (Fig. 5C ,
lane 4 versus 3). To further verify the effect of phosphorylation on
hEXO1b, we used the phosphatase inhibitor okadaic acid. Addition
of okadaic acid to hydroxyurea-treated cells resulted in a more
pronounced decrease of hEXO1b electrophoretic mobility and
drastically compromised hEXO1b stability (Fig. 5D , lane 5 versus
4). Taken together, these data suggested that a correlation existed
between phosphorylation and ubiquitin-dependent degradation of
hEXO1b upon hydroxyurea treatment.
Discussion
DNA replication and DNA repair are complex cellular
processes requiring functional assembly and tight regulation of
large protein complexes. DNA metabolism and the cell division
cycle are highly coordinated, with checkpoint pathways acting as
interface between them (24). These pathways not only ensure that
DNA synthesis and repair are completed before critical transitions
in the cell cycle but they are also involved in controlling the
assembly of DNA repair complexes at sites of DNA damage.
Defects in checkpoint control cause a wide spectrum of
phenotypes, with lethality resulting from ATR or CHK1 deficiency
and pathologic conditions arising from the lack of ATM or CHK2
function (25).
Here, we have examined the regulation of hEXO1b, a mismatch
repair–associated exonuclease, the yeast homologue of which is
responsible for generating long tracts of ssDNA at stalled
replication forks (26) and unprotected telomere ends (27). Our
data showed that, in synchronized cells, hEXO1b was constantly
expressed throughout the cell division cycle. Given its role as DNA
processing enzyme, the presence of hEXO1b in the S phase induces
to speculate that it might be either present at forks but subject to
tight regulation, or absent from moving forks of replication and
selectively recruited upon stalling. Data obtained upon ectopic
expression of hEXO1 in mouse fibroblasts (19) favor the former
model, whereas evidence obtained in yeast supports the latter (28).
Studies aimed at addressing the localization of endogenous
hEXO1b in human cells are currently ongoing in our laboratory.
Despite the evident stability of hEXO1b throughout the cell cycle, in
this study we found that the level of hEXO1b was significantly
reduced upon treatment of cells with hydroxyurea or aphidicolin,
two agents that cause replication fork arrest by different
mechanisms. Addition of aphidicolin to S-phase–synchronized
cells led to rapid reduction of hEXO1b protein level. This was not
the case if the drug was added to cells transiting from M to G1, thus
indicating that the response to aphidicolin was not merely the
result of stress but was specifically linked to DNA synthesis
inhibition. Removal of the block and resumption of progression
through S phase was accompanied by resynthesis of hEXO1b,
suggesting that the process was fully reversible. Moreover, the fact
that rapid degradation of hEXO1b was observed in response to
DNA replication arrest but not upon treatment with agents that
can directly induce DNA damage ruled out a role for signals from
secondary lesions that may arise as consequence of fork arrest. At
the molecular level, evidence obtained with the inhibitor MG132
pointed to an involvement of the proteasome in the process of
hEXO1b degradation. This finding was substantiated by the
appearance of polyubiquitinylated forms of hEXO1b only in
hydroxyurea-treated cells. In addition to ubiquitinylation, we found
that hEXO1b was a phospho-protein and that the extent of
phosphorylation was increased in response to hydroxyurea.
Phosphorylation of hEXO1b correlated with its rapid degradation
and this was rescued by caffeine, thus implicating a role for ATM/
ATR kinases in this process. Inhibition of DNA replication in rad53-
deficient yeast strains was shown to result in hemireplicated
intermediates with large regions of ssDNA (29). This indicated that
the integrity of stalled replication forks was maintained by tight
control of an exonuclease activity in wild type, but not in rad53
strains. Colocalization studies have shown that the nucleases
hMRE11 (30) and hFEN1 (31) interact with RPA and PCNA at forks
of replication. These nucleases, however, are stable proteins
participating in formation of nuclear foci during DNA synthesis
or DNA repair (30, 32). Colocalization of ectopically expressed
hEXO1 with PCNA was shown to occur in mouse fibroblasts (19).
Recent evidence obtained in yeast confirmed the recruitment of
exonuclease 1 to stalled forks (28). Our data show that hEXO1b is
degraded in response to stalled replication and prompt to
hypothesize that ATR/CHK1–dependent signaling might play a
key role in the regulation of hEXO1. Such hypothesis is supported
by published data showing that activation of Mec1, the S. cerevisiae
ATR ortholog, occurred upon generation of long tracts of ssDNA by
Exo1p (26). Future studies will aim at clarifying the possible role of
ATR-dependent signals on the regulation of hEXO1b stability.
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